Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed
in new markets - Fresenius Medical Care
for further growth - Fresenius Kabi
for better health - Fresenius Helios
for greater efficiency - Fresenius Vamed
close

Seizing opportunities > in new markets

Asia is an important growth market for Fresenius Medical Care. Approximately 620,000 patients with chronic kidney failure are currently being treated in this region, and every year this number increases by about 10 to 11%. We will continue to take advantage of this growth potential. The significant demand for dialysis services offers substantial opportunities to expand our network of clinics in the Asian countries.

In 2008, Fresenius Medical Care achieved sales of US$ 606 million in the Asia-Pacific region. Our goal is to continue our strong organic growth and to increase sales to more than US$ 800 million in constant currency by 2010.

FRESENIUS MEDICAL CARE IN ASIA
  2008 2007 Change
Sales (in million US$) 606 541 12%
Employees (December 31) 3,558 3,095 15%
Dialysis patients (December 31) 9,158 7,789 18%
Dialysis treatments (million) 1.34 1.21 11%
Dialysis clinics (December 31) 125 105 19%
 

READ MORE ABOUT FRESENIUS MEDICAL CARE >>

close
in new markets - Fresenius Medical Care
close

Seizing opportunities > for further growth

With the acquisition of APP Pharmaceuticals, Fresenius Kabi has achieved a leading position in the global market for intravenously administered generic drugs. APP Pharmaceuticals has a strong drug registration portfolio pending and over 70 products under development, opening up new growth opportunities.

At the same time, we are seizing the opportunity of introducing selected Kabi products into the US, with initial focus on parenteral nutrition. We are also planning to launch selected APP IV drugs outside the US.

APP PHARMACEUTICALS IN FIGURES
  2008
Sales US$ 777 million
EBITDA, adjusted* US$ 317 million
EBITDA margin, adjusted* 40.8%
Employees (December 31, full-time equivalent) 1,487
Production facilities 3
Produkte >100
Number of products ~17%
 

READ MORE ABOUT FRESENIUS KABI >>

close
for further growth - Fresenius Kabi
close

Seizing opportunities > for better health

At Fresenius Helios, our commitment is to provide the highest medical quality and care. We aim to offer advanced and proven best-in-class diagnosis and treatment methods for the benefit of our patients. We continuously invest in high-quality, state-of-the-art medicine, and aim to measure and improve the quality of medical care.

Our target ist that our quality indicators should be better than the German average. With a mortality rate of SMR < 1, this was accomplished, among others, for major illnesses shown below.

HELIOS QUALITY INDICATORS
Indications/
standardized mortality rate (SMR)*
2008
SMR
2007
SMR
Acute myocardial infarction 0.73 0.79
Heart failure 0.73 0.85
Stroke 0.83 1.01
Acute cerebral infarction 0.81 0.99
Pneumonia 0.71 0.85
 

READ MORE ABOUT FRESENIUS HELIOS >> 

close
for better health - Fresenius Helios
close

Seizing opportunities > for greater efficiency

Fresenius Vamed is a leading international provider of services in the planning, construction, and management of health care facilities. Our complete value chain and our more than 25 years of international experience are key to providing effective support for hospitals at every stage of their life cycle, and thus contributing towards their successful operating performance. For us, each project is another opportunity to prove our competence.

Hospitals face the dual challenge of increasing efficiency and reducing expenditure. We support hospitals by offering comprehensive process know-how and by taking over medical-technical services and management functions.

VAMED SERVICES
   
Service contracts* for   140 clinics
  ~ 50,000 beds
among others:  
Vienna General Hospital and University Clinics (AKH) ~ 2,100 beds
Charité Hospital Berlin ~ 3,200 beds
University Clinic Hamburg-Eppendorf ~1,370 beds
Prince Court Medical Center, Kuala Lumpur ~ 330 beds
Al Ain Hospital, Abu Dhabi ~ 450 beds
 

READ MORE ABOUT FRESENIUS VAMED >>

close
for greater efficiency - Fresenius Vamed
  • Print page
  • Save as PDF
  • Add to Cart
  • Recommend Page

Print

38. INFORMATION ON THE SUPERVISORY BOARD

The Supervisory Board appoints the members of the Management Board and supervises and advises the Management Board in managing the Company. However, the Supervisory Board is fundamentally prohibited from managing the Company in any way. The compensation of the Supervisory Board is determined by the Annual General Meeting and is subject to the provisions contained in Section 14 of the Articles of Association of Fresenius SE. Each member of the Supervisory Board shall receive a fixed compensation of € 13 thousand. The members of the Audit Committee and the Personnel Committee of the Supervisory Board receive an additional € 10 thousand each and the Chairman of the committee a further € 10 thousand. For each full fiscal year, the remuneration increases by 10% for each percentage point that the dividend paid on each ordinary share for that year (gross dividend according to the resolution of the Annual General Meeting) exceeds 3.6% of the amount equal to the subscribed capital divided by the number of nonpar value shares; residual amounts are interpolated. The Chairman receives twice this amount and the deputies to the Chairman one and a half times the amount of a Supervisory Board member. All members of the Supervisory Board receive appropriate compensation for costs of travel and accommodation incurred in connection with their duties as members of the Supervisory Board. Fresenius SE provides to the members of the Supervisory Board insurance coverage in an adequate amount (relating to their function) and on an adequate excess amount basis.

For the years 2008 and 2007, the compensation for the members of the Supervisory Board of Fresenius SE were as follows:

  Fixed
compensation 
Compensation for
commitee services
Variable
compensation 
Total
compensation
in thousand € 2008 2007 2008 2007 2008 2007 2008 2007
Dr. Gerd Krick 26 26 30 25 173 162 229 213
Dr. Dieter Schenk 20 16 0 0 129 100 149 116
Niko Stumpfögger
(since July 16, 2007)
20 8 0 0 129 49 149 57
Prof.Dr. h.c. Roland Berger
(since May 21, 2008)
8 0 12 0 53 0 73 0
Gerhard Herres
(until July 13, 2007)
0 7 0 0 0 43 0 50
Dario Ilossi
(since July 16, 2007)
13 6 0 0 86 38 99 44
Konrad Kölbl
(since July 16, 2007)
13 6 10 3 86 38 109 47
Dr. Gabriele Kröner
(until May 21, 2008)
5 13 0 0 33 81 38 94
Dr. Bernd Mathieu
(until July 13, 2007)
0 7 0 0 0 43 0 50
Klaus-Peter Müller
(since May 21, 2008)
8 0 0 0 53 0 61 0
Christel Neumann
(until July 13, 2007)
0 7 0 0 0 43 0 50
Ilona Oesterle
(until July 13, 2007)
0 7 0 0 0 43 0 50
Dr. Gerhard Rupprecht 13 13 0 0 86 81 99 94
Wilhelm Sachs 13 13 10 3 86 80 109 96
Dr. Karl Schneider 13 13 20 11 86 81 119 105
Stefan Schubert
(since July 16, 2007)
13 6 0 0 86 38 99 44
Rainer Stein
(since July 16, 2007)
13 6 10 3 86 38 109 47
Volker Weber
(until July 13, 2007)
 0  10 0 11
0 64
0
85
Dr. Bernhard Wunderlin
(until May 21, 2008)
5 13 8 16 33 81 46 110
Total 183 177 100 72 1,205 1,103 1,488 1,352